FDA Approved: TAKHZYRO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TAKHZYRO (lanadelumab-flyo) from Takeda Pharmaceuticals America, Inc., to update and expand its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Takhzyro (lanadelumab)

Snippet

SUPPL AP for TAKHZYRO (LANADELUMAB-FLYO)